Voyager Therapeutics is trading at $1.81, down 10.40%, alongside broad market weakness. - The supplied alert reports Nasdaq down 2.19% and the S&P 500 down 1.37%. - Reuters reported renewed pressure on growth stocks amid AI-spending concerns and rising oil prices. - The latest company-specific news was an October 21 management change: Robin Swartz was appointed president and is expected to succeed the CEO in Q1 2027. No source found directly ties the announcement to the October 22 decline.